A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 04 Sep 2019 Status changed from recruiting to suspended.
- 31 Aug 2018 Biomarkers information updated
- 12 Apr 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.